Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AAPL
6. HOOD
7. QCOM
8. ACN
9. AZN
10. ROIV

Go back to Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
(NASDAQ: VTRS) Delayed: 16.61 -0.27 (1.6%)
Previous Close $16.88    52 Week High $ 
Open $16.63    52 Week Low $ 
Day High $16.77    P/E N/A 
Day Low $16.42    EPS $ 
Volume 4,394,622